The developer of sustained acoustic medicine technology and the sam® wearable ultrasound device and number one resource for arthritis information will support the Foundation's efforts to provide resources and education to patients, families and caregivers.
Read More
This agreement will introduce a new technology that has already demonstrated strong results in promoting wound healing to the United States.
Read More
FibroMAP combines the power of high-resolution, single-fiber, and spatially resolved datasets generated by PharmaNest's digital pathology and image analysis platform (FibroNest) with advanced clustering techniques such as Uniform Manifold Approximation and Projection (UMAP) to interpret complex, high-dimensional data. FibroMAP is poised to revolutionize the study of fibrosis histology in the same way that single-cell analysis transformed biology.
Read MoreEach ID combines the lifesaving simplicity of custom engraving with the power of a scannable QR code, giving wearers instant access to their full online health record when it matters most.
Read MoreAcquisitions are On Track and Progressing From Signing to Closing; Guidance of $65M+ In Pro Forma Revenues Remains In Place
TRNR Expects to Provide Positive Update on Sportstech Q1 2025 Performance in May 2025
Read MoreReports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52)
Reiterates 2025 expected revenue range of $1.5 to $2.5 billion and 2025 year-end cash balance of approximately $6 billion
Announces reduction of $1.4 to $1.7 billion in estimated GAAP operating costs by 2027
Advancing up to 10 products toward approval, including multiple oncology candidates
Read More
Mentavi, a national leader in online mental health testing, will attend the 10th World Congress on ADHD and present a first-ever study comparing the accuracy and validity of an online asynchronous assessment for diagnosing ADHD in adults with the current standard of care, a clinical interview.
Read More“We are not just challenging DEA policy, we are defending the Constitution said Duane Boise, CEO of MMJ BioPharma Cultivation. The DEA cannot sidestep Supreme Court precedent and force us into a hearing. The agency is running a closed loop of power, Boise added, they investigate, prosecute, judge and override all in-house. That’s not justice, that’s a rigged game.”
Read MoreCompany Confirms Both Acquisitions are On Track and Progressing From Signing to Closing, Reiterates Guidance of $65M+ Pro Forma Revenues
TRNR to Provide Positive Update on Sporstech Q1 2025 Performance in May 2025
Read MoreThe webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for crofelemer for MVID; Click here to register
There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management
This data was presented at the Annual ELITE PED-GI Congress by Dr. Mohamad Miqdady, a recognized leader in pediatric gastroenterology and the primary investigator for this study
Read More- Rigorous humanized mouse model enhances credibility and translatability of results
- Key preclinical data to support FDA Orphan Drug Application
- In vitro success signals potential for exosome-based therapy breakthrough
Read MoreNew offering empowers hospitals to enhance clinical excellence, streamline operations, and helps secure sustainable financial growth without disrupting existing clinician employment models.
Read MorePatient Enrollment will Begin Shortly; First Live Patient Surgeries are Anticipated within 90 Business Days
Critical Milestone Achieved for Multi-Center Clinical Trial in India with Strategic Partner Shalby Hospitals for the mBȏs TKA System
Read MoreThe webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for crofelemer for MVID; Click here to register
There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management
This data was presented at the Annual ELITE PED-GI Congress by Dr. Mohamad Miqdady, a recognized leader in pediatric gastroenterology and the primary investigator for this study
Read More
